Objective Gliomas are the most common malignant tumors in the central nervous system.Despite multiple therapies including surgery,chemotherapy,and radiotherapy,the prognosis of patients remains poor.Immunotherapy is an alternative method of treating glioma,and the use of dendritic cell vaccines is one of the promising treatment options.However,there is no specific tumor cell antigen that can trigger dendritic cells(DCs).IL-13Ra2 is a specific antigen expressed in glioma cells;in the current study,we have attempted to explore whether IL-13Ra2 could be the antigen that triggers DCs and to envisage its application as potential therapy for glioma.Methods The expression of IL-13Ra2 was detected in U251 glioma cell lines and primary glioma tissues using different methods.DCs from human blood were isolated and pulsed with recombinant IL-13Ra2,following which the cytotoxicity of these DCs on glioma cells was detected and analyzed.Results About 55.9% human glioma tissue cells expressed IL-13Ra2,while normal brain tissue cells did not show any expression.DC vaccines loaded with IL-13Ra2,glioma cell antigen,and brain tumor stem cell(BTSC) antigen could significantly stimulate the proliferation of T lymphocytes and induce cell death in the glioma tissue.Compared to other groups,DC vaccines loaded with BTSC antigen showed the strongest ability to activate cytotoxic T lymphocytes(CTLs),while the glioma cell antigen group showed no significant difference.Conclusion IL-13Ra2,which is expressed in gliomas and by glioma stem cells,as well as IL-13Ra2 could prove to be potential antigens for DC vaccine-based immunotherapy. Objective Gliomas are the most common malignant tumors in the central nervous system. Graduate multiple therapies including surgery, chemotherapy, and radiotherapy, the prognosis of patients remains poor. Immunotherapy is an alternative method of treating glioma, and the use of dendritic cell vaccines is one of the promising treatment options. Despite, there is no specific tumor cell antigen that can trigger dendritic cells (DCs). IL-13Ra2 is a specific antigen expressed in glioma cells; in the current study, we have attempted to explore whether IL-13Ra2 could be the antigen that triggers DCs and to envisage its application as potential therapy for glioma. Methods The expression of IL-13Ra2 was detected in U251 glioma cell lines and primary glioma tissues using different methods. DCCs from human blood were isolated and pulsed with recombinant IL-13Ra2, following which the cytotoxicity of these DCs on glioma cells was detected and analyzed. Results about 55.9% human glioma tissue cells expressed IL-13Ra2 , while normal brain tissue cells did not show any expression. DC vaccines loaded with IL-13Ra2, glioma cell antigen, and brain tumor stem cells (BTSC) antigen could significantly stimulate the proliferation of T lymphocytes and induce cell death in the glioma tissue. Compared to other groups, DC vaccines loaded with BTSC antigen showed the strongest ability to activate cytotoxic T lymphocytes (CTLs), while the glioma cell antigen group showed no significant difference. Conlusion IL-13Ra2, which is expressed in gliomas and by glioma stem cells As well as IL-13Ra2 could prove to be potential antigens for DC vaccine-based immunotherapy.